ijms-logo

Journal Browser

Journal Browser

Drug Development in the Prevention and Treatment of COVID-19

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (30 September 2024) | Viewed by 1738

Special Issue Editors


E-Mail Website
Guest Editor
Department of Occupational Medicine, Local Health Authority, Lecce, Italy
Interests: occupational health; epidemiology; public health; shift work
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
1. Department of Public Health and Infectious Diseases, University of Rome “Sapienza”, Rome, Italy
2. Azienda Policlinico Umberto I, 00161 Rome, Italy
Interests: HIV; nutrition; probiotics; microbiota; immune response; gender; quality of life; NCCD
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
University Hospital Policlinico Umberto I, University of Rome Sapienza, Rome, Italy
Interests: infectious diseases; global health; migrants; difficult to treat infection; multidrug resistant organisms; MDROs; antibiotics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Infectious disease (ID) control represents a focus of global health policy, as IDs are significantly associated with morbidity and mortality and are among the top leading causes of death worldwide. The emergence of new bacteria and viruses, such as SARS-CoV-2, has been identified as a threat to global public health with a high economic and social burden. Although enormous progress has been made in knowledge, prevention, and antimicrobial therapy, minimizing the human and economic cost of IDs, even before the COVID-19 pandemic, was a special challenge for public health. To date, despite the availability of anti-infectious therapies, antimicrobial resistance threatens the efficacy of several current antimicrobial agents. In addition, the unclear pathogenesis and host-related adverse reactions hinder the discovery of novel anti-infectious therapeutics. The update on research advances in IDs focusing on mechanistic topics is pivotal in order to identify preventive and therapeutic strategies aimed at minimizing the impact of IDs. The research on the present topic is of particular interest, but at the same time challenging, since it deals with new horizons for infectious disease research.

Prof. Dr. Gabriele D’Ettorre
Dr. Gabriella D’Ettorre
Dr. Giancarlo Ceccarelli
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antimicrobial therapy
  • antimicrobial resistance
  • preventive strategies
  • precision medicine
  • drug development

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

8 pages, 745 KiB  
Communication
Could SP-A and SP-D Serum Levels Predict COVID-19 Severity?
by Luca Maddaloni, Veronica Zullino, Ginevra Bugani, Alessandro Lazzaro, Matteo Brisciani, Claudio Maria Mastroianni, Letizia Santinelli and Franco Ruberto
Int. J. Mol. Sci. 2024, 25(11), 5620; https://doi.org/10.3390/ijms25115620 - 22 May 2024
Cited by 1 | Viewed by 1257
Abstract
Given the various clinical manifestations that characterize Coronavirus Disease 2019 (COVID-19), the scientific community is constantly searching for biomarkers with prognostic value. Surfactant proteins A (SP-A) and D (SP-D) are collectins that play a crucial role in ensuring proper alveolar function and an [...] Read more.
Given the various clinical manifestations that characterize Coronavirus Disease 2019 (COVID-19), the scientific community is constantly searching for biomarkers with prognostic value. Surfactant proteins A (SP-A) and D (SP-D) are collectins that play a crucial role in ensuring proper alveolar function and an alteration of their serum levels was reported in several pulmonary diseases characterized by Acute Respiratory Distress Syndrome (ARDS) and pulmonary fibrosis. Considering that such clinical manifestations can also occur during Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, we wondered if these collectins could act as prognostic markers. In this regard, serum levels of SP-A and SP-D were measured by enzyme immunoassay in patients with SARS-CoV-2 infection (n = 51) at admission (T0) and after seven days (T1) and compared with healthy donors (n = 11). SP-D increased in COVID-19 patients compared to healthy controls during the early phases of infection, while a significant reduction was observed at T1. Stratifying SARS-CoV-2 patients according to disease severity, increased serum SP-D levels were observed in severe compared to mild patients. In light of these results, SP-D, but not SP-A, seems to be an eligible marker of COVID-19 pneumonia, and the early detection of SP-D serum levels could be crucial for preventive clinical management. Full article
(This article belongs to the Special Issue Drug Development in the Prevention and Treatment of COVID-19)
Show Figures

Figure 1

Back to TopTop